Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um Estudo para Investigar a Segurança, Farmacocinética e Eficácia Preliminar da Terapia com IDE574 em Participantes Adultos com Tumores Sólidos Avançados

2 de novembro de 2026 atualizado por: IDEAYA Biosciences

An Open Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of IDE574 as Monotherapy in Locally Advanced or Metastatic Solid Tumors and as Combination Therapy With Fulvestrant in Locally Advanced or Metastatic Cancer

IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7.

The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants with locally advanced or metastatic solid tumors and as combination therapy with fulvestrant in participants with advanced or metastatic cancer.

Visão geral do estudo

Status

Recrutamento

Condições

Descrição detalhada

Part 1 - Monotherapy Dose Escalation and Expansion:

Part 1A - Monotherapy Dose Escalation Part 1A will evaluate increasing doses of IDE574 to assess safety, tolerability and to determine dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD) or the recommended dose for expansion (RDE) in subjects with advanced or metastatic cancer.

Part 1B - Monotherapy Dose Expansion Part 1B will evaluate in ER+ HER2- advanced or metastatic cancer at one RDE determined from Part 1A or the MTD.

Part 1C - Exploratory Food Effect Sub-study

Part 2 - Combination Dose Escalation and Expansion

Part 2A - IDE574 Combination Therapy with Fulvestrant Dose Escalation Part 2A will evaluate participants with advanced or metastatic cancer with escalating doses of IDE574 in combination with fulvestrant to assess safety, tolerability and to determine DLTs, MTD or RDE.

Part 2B - IDE574 Combination Therapy with Fulvestrant Dose Expansion Part 2B will randomly assign participants with advanced or metastatic cancer to dose levels selected from Part 2A

Tipo de estudo

Intervencional

Inscrição (Estimado)

155

Estágio

  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • California
      • Santa Monica, California, Estados Unidos, 90404-2095
        • Ativo, não recrutando
        • UCLA - Parkside Cancer Center
    • Connecticut
      • New Haven, Connecticut, Estados Unidos, 06510-3206
        • Recrutamento
        • Yale School of Medicine - Cedar Street
        • Investigador principal:
          • Patricia LoRusso, MD
        • Contato:
    • Florida
      • Plantation, Florida, Estados Unidos, 33322
        • Recrutamento
        • Florida Clinical Trials Group
        • Investigador principal:
          • Harshad Amin, MD
        • Contato:
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322-1013
        • Recrutamento
        • Winship Cancer Institute, Emory University
        • Investigador principal:
          • Shipra Gandhi, MD
        • Contato:
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63110-1010
        • Recrutamento
        • Washington University - Siteman Cancer Center
        • Investigador principal:
          • Faisal Fa'ak, MD
        • Contato:
    • New Jersey
      • East Brunswick, New Jersey, Estados Unidos, 08816
        • Recrutamento
        • START Astera, LLC
        • Investigador principal:
          • Bruno Fang, MD
        • Contato:
    • New York
      • Lake Success, New York, Estados Unidos, 11042
        • Recrutamento
        • START New York Long Island, LLC
        • Investigador principal:
          • Geraldine O'Sullivan Coyne, MD
        • Contato:
      • New York, New York, Estados Unidos, 10032-3729
        • Ativo, não recrutando
        • Columbia University Medical Center -161 Fort Washington
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37203
        • Recrutamento
        • SCRI Oncology Partners - PPDS
        • Investigador principal:
          • Sarah Premji, MD
        • Contato:
    • Texas
      • Austin, Texas, Estados Unidos, 78758
        • Recrutamento
        • NEXT Texas LLC - Austin
        • Investigador principal:
          • Sheena Sahota, MD
        • Contato:
      • Dallas, Texas, Estados Unidos, 75039
        • Recrutamento
        • NEXT Texas LLC - Dallas
        • Investigador principal:
          • Faran Polani, MD
        • Contato:
      • Fort Worth, Texas, Estados Unidos, 76104
        • Recrutamento
        • START Dallas Fort Worth, LLC
        • Investigador principal:
          • Henry Xiong, MD
        • Contato:
      • Houston, Texas, Estados Unidos, 77030-4009
        • Recrutamento
        • MD Anderson Cancer Center
        • Investigador principal:
          • Timothy Yap, MD
        • Contato:
      • Houston, Texas, Estados Unidos, 77054
        • Recrutamento
        • NEXT Texas LLC - Houston
        • Investigador principal:
          • Jennifer Segar, MD
        • Contato:
      • San Antonio, Texas, Estados Unidos, 78229
        • Recrutamento
        • NEXT Texas LLC - San Antonio
        • Investigador principal:
          • David Sommerhalder, MD
        • Contato:
      • San Antonio, Texas, Estados Unidos, 78229
        • Recrutamento
        • Start San Antonio, LLC
        • Investigador principal:
          • Amita Patnaik, MD
        • Contato:
    • Utah
      • West Valley City, Utah, Estados Unidos, 84119
        • Recrutamento
        • START Mountain Region, LLC
        • Investigador principal:
          • William McKean, MD
        • Contato:
    • Virginia
      • Fairfax, Virginia, Estados Unidos, 22031
        • Recrutamento
        • NEXT Virginia
        • Investigador principal:
          • Mohamad Salkeni, MD
        • Contato:
    • K'alak'i T'bilisi
      • Batumi, K'alak'i T'bilisi, Geórgia, 6000
        • Recrutamento
        • High Technology Hospital MedCenter Ltd
        • Investigador principal:
          • Tamta Makharadze, MD
        • Contato:
      • Tbilisi, K'alak'i T'bilisi, Geórgia, 114
        • Recrutamento
        • Pineo Medical Ecosystem
        • Contato:
        • Investigador principal:
          • Mziuri Zakaraia, MD
      • Tbilisi, K'alak'i T'bilisi, Geórgia, 112
        • Ativo, não recrutando
        • LLC ARENSIA Exploratory Medicine
      • Tbilisi, K'alak'i T'bilisi, Geórgia, 144
        • Ativo, não recrutando
        • Geo Hospitals Multiprofile Medical Center Tbilisi
      • Tbilisi, K'alak'i T'bilisi, Geórgia, 186
        • Ativo, não recrutando
        • LLC Caucasus Medical Centre

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 99 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

Archival Tissue sample for testing

  • Part 1A - Participants with advanced or metastatic cancer who have progressed on/after standard of care therapy or are intolerant to additional effective therapies.
  • Female participants with cancer considered to be of childbearing potential (or have tubal ligations only) must be willing to undergo medically induced menopause (Parts 2A and B only)
  • Female participants of nonchildbearing potential with cancer must meet at least 1 of the following criteria: Age ≥ 60 years or age <60 years with absence of menstruation for at least 12 months, or had prior removal of both ovaries
  • Have Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤1.
  • Have adequate bone marrow, renal and liver function.
  • Life expectancy of >3 months
  • Able to safely administer and retain orally administered study treatment
  • Able to comply with contraceptive/barrier requirements

Key Exclusion Criteria:

  • Known symptomatic brain metastases or leptomeningeal metastasis
  • Known primary CNS malignancy and any other malignancies within 2 years prior to the first dose with the exception of adequately treated localized tumor.
  • Have impairment of GI function or GI disease that may significantly alter the absorption of IDE574.
  • Have active liver or biliary disease.
  • Have active, uncontrolled bacterial, fungal, or viral infection
  • Have clinically significant cardiac abnormalities and/or blood clotting events within 6 months before the first dose
  • If participants had adverse reactions to previous experimental antitumor treatment that have not recovered to Grade ≤ 1
  • Prior irradiation to >25% of the bone marrow.
  • Known or suspected hypersensitivity to IDE574/excipients or components (Parts 1 & 2) or fulvestrant/excipients or components (Part 2 only)

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Monotherapy Dose Escalation (Part 1A)

Participants with the appropriate tumor types will be treated with escalating doses of IDE574

IDE574

Experimental: Monotherapy Dose Expansion (Part 1B)

Participants with advanced or metastatic cancer will be treated using the RDE or MTD of IDE574

IDE574

Experimental: Combination Dose Escalation (Part 2A) IDE574 + Fulvestrant

Participants with advanced or metastatic cancer will be treated with escalating doses of IDE574 in combination with fulvestrant

IDE574

Fulvestrant Injection

Experimental: Combination Dose Expansion (Part 2B)

Participants with advanced or metastatic cancer will be randomly assigned to doses of IDE574 + Fulvestrant

IDE574

Fulvestrant Injection

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Safety and Tolerability of IDE574 in Part 1 A Monotherapy Dose escalation
Prazo: Following the first dose of IDE574

incidence of DLT; incidence and severity of AEs/serious adverse events (SAEs) graded based on CTCAE V6.0

Following the first dose of IDE574
Safety and Tolerability of IDE574 in Part 1B Monotherapy Dose expansion based on incidence and severity of AEs/SAEs
Prazo: total study duration

Incidence and severity of AEs/SAEs graded based on CTCAE V6.0

total study duration
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on the ORR per RECIST version 1.1
Prazo: total study duration

Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

total study duration
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on DOR per RECIST version 1.1.
Prazo: total study duration

Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

total study duration
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2A Combination Dose Escalation based on incidence of DLT
Prazo: total study duration

Incidence of DLT; incidence and severity of AEs/SAEs graded based on CTCAE V6.0

total study duration
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the incidence and severity of AEs/SAEs
Prazo: total study duration

Incidence and severity of AEs/SAEs graded based on CTCAE V6.0

total study duration
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the ORR per RECIST version 1.1
Prazo: total study duration

Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

total study duration
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on DOR per RECIST version 1.1.
Prazo: total study duration

Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

total study duration

Medidas de resultados secundários

Medida de resultado
Prazo
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on the ORR per RECIST version 1.1
Prazo: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on DOR per RECIST version 1.1.
Prazo: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Clinical Benefit Rate (CBR)
Prazo: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Disease control rate
Prazo: total study duration
total study duration
Evaluate the pharmacokinetics (PK) of IDE574 in Part 1A Monotherapy Dose Escalation
Prazo: total study duration
total study duration
Evaluate the PK of IDE574 in Part 1B Monotherapy Dose Expansion
Prazo: total study duration
total study duration
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion
Prazo: total study duration
total study duration
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion based on DCR for other solid tumor types
Prazo: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on ORR per RECIST version 1.1
Prazo: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on DOR per RECIST version 1.1
Prazo: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on CBR per RECIST version 1.1
Prazo: total study duration
total study duration
Evaluate the PK of IDE574 in Part 2A Combination Dose Escalation
Prazo: total study duration
total study duration
Evaluate antitumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on CBR per RECIST version 1.1
Prazo: total study duration
total study duration
Evaluate the PK of IDE574 in Part 2B Combination Dose Expansion
Prazo: total study duration
total study duration

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

17 de março de 2026

Conclusão Primária (Estimado)

31 de dezembro de 2029

Conclusão do estudo (Estimado)

31 de janeiro de 2030

Datas de inscrição no estudo

Enviado pela primeira vez

1 de abril de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

14 de abril de 2026

Primeira postagem (Real)

20 de abril de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

5 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

2 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Outros números de identificação do estudo

  • IDE574-001
  • 178299 (Outro identificador: Regulatory Agency Identifier Number (s))

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever